| Integrative genomic profiling of human prostate cancer BS Taylor, N Schultz, H Hieronymus, A Gopalan, Y Xiao, BS Carver, ... Cancer cell 18 (1), 11-22, 2010 | 4177 | 2010 |
| NF-κB as a therapeutic target in multiple myeloma T Hideshima, D Chauhan, P Richardson, C Mitsiades, N Mitsiades, ... Journal of Biological Chemistry 277 (19), 16639-16647, 2002 | 1195 | 2002 |
| Molecular sequelae of proteasome inhibition in human multiple myeloma cells N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, G Fanourakis, X Gu, ... Proceedings of the National Academy of Sciences 99 (22), 14374-14379, 2002 | 951 | 2002 |
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications N Mitsiades, CS Mitsiades, PG Richardson, V Poulaki, YT Tai, D Chauhan, ... Blood, The Journal of the American Society of Hematology 101 (6), 2377-2380, 2003 | 948 | 2003 |
| A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ... Cancer cell 8 (5), 407-419, 2005 | 856 | 2005 |
| Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, PG Richardson, ... Blood, The Journal of the American Society of Hematology 99 (12), 4525-4530, 2002 | 843 | 2002 |
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ... Cancer cell 5 (3), 221-230, 2004 | 799 | 2004 |
| Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression A M. Joussen, V Poulaki, N Mitsiades, B Kirchhof, K Koizumi, S Döhmen, ... The FASEB journal 16 (3), 438-440, 2002 | 774 | 2002 |
| Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ... Blood, The Journal of the American Society of Hematology 101 (4), 1530-1534, 2003 | 763 | 2003 |
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ... Proceedings of the National Academy of Sciences 101 (2), 540-545, 2004 | 677 | 2004 |
| Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications CS Mitsiades, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, ... Oncogene 21 (37), 5673-5683, 2002 | 639 | 2002 |
| Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model R LeBlanc, LP Catley, T Hideshima, S Lentzsch, CS Mitsiades, ... Cancer research 62 (17), 4996-5000, 2002 | 637 | 2002 |
| Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity N Mitsiades, W Yu, V Poulaki, M Tsokos, I Stamenkovic Cancer research 61 (2), 577-581, 2001 | 547 | 2001 |
| Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal … AM Joussen, V Poulaki, W Qin, B Kirchhof, N Mitsiades, SJ Wiegand, ... The American journal of pathology 160 (2), 501-509, 2002 | 510 | 2002 |
| Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, PG Richardson, ... Blood, The Journal of the American Society of Hematology 99 (11), 4079-4086, 2002 | 506 | 2002 |
| TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications CS Mitsiades, SP Treon, N Mitsiades, Y Shima, P Richardson, ... Blood, The Journal of the American Society of Hematology 98 (3), 795-804, 2001 | 506 | 2001 |
| Antimyeloma activity of heat shock protein-90 inhibition CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, AL Kung, FE Davies, ... Blood 107 (3), 1092-1100, 2006 | 407 | 2006 |
| Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity DW McMillin, J Delmore, E Weisberg, JM Negri, DC Geer, S Klippel, ... Nature medicine 16 (4), 483-489, 2010 | 388 | 2010 |
| Molecular sequelae of histone deacetylase inhibition in human malignant B cells N Mitsiades, CS Mitsiades, PG Richardson, C McMullan, V Poulaki, ... Blood, The Journal of the American Society of Hematology 101 (10), 4055-4062, 2003 | 369 | 2003 |
| Immunomodulatory drug costimulates T cells via the B7-CD28 pathway R LeBlanc, T Hideshima, LP Catley, R Shringarpure, R Burger, ... Blood 103 (5), 1787-1790, 2004 | 361 | 2004 |
Galinos FanourakisNational and Kapodistrian University of AthensBestätigte E-Mail-Adresse bei med.uoa.gr